votubia
Preclinical
Novartisvotubia is one of 3 therapeutic programs targeting Angiomyolipoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
2 competitors in Angiomyolipoma
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for votubia. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company